{"id":249802,"date":"2023-09-12T00:00:00","date_gmt":"2023-09-12T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneop0008-2023-biopharma-glaucoma-unmet-need-detailed-expanded\/"},"modified":"2026-05-10T11:22:38","modified_gmt":"2026-05-10T11:22:38","slug":"unneop0008-2023-biopharma-glaucoma-unmet-need-detailed-expanded-analysis-us-eu","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneop0008-2023-biopharma-glaucoma-unmet-need-detailed-expanded-analysis-us-eu\/","title":{"rendered":"Glaucoma &#8211; Unmet Need &#8211; Detailed, Expanded Analysis (US\/EU)"},"content":{"rendered":"<p>Glaucoma is a progressive disease of the optic nerve caused by high intraocular pressure (<abbr data-abbreviation-entity=\"6402\" title=\"intraocular pressure\">IOP<\/abbr>); it is one of the leading causes of vision loss in the United States and Europe. The majority of glaucoma patients have primary open-angle glaucoma (<abbr title=\"primary open-angle glaucoma\">POAG<\/abbr>). Treatment of <abbr title=\"primary open-angle glaucoma\">POAG<\/abbr> aims to lower and stabilize <abbr title=\"intraocular pressure\">IOP<\/abbr>; pharmacotherapy is widely used for this purpose. The pharmaceutical market for <abbr title=\"primary open-angle glaucoma\">POAG<\/abbr> is broad and highly genericized. Prostaglandin analogues, such as latanoprost and bimatoprost are the long-standing first-class treatment option for <abbr title=\"primary open-angle glaucoma\">POAG<\/abbr> due to their demonstrated efficacy, safety, and once-per-day self-administration. Beta blockers such as timolol are widely used as follow-up therapies; other later-line agents include alpha agonists and carbonic anhydrase inhibitors. In 2018, <a>Alcon\u2019s<\/a> (formerly Aerie\u2019s) first-in-class Rhopressa (netarsudil) received <abbr title=\"Food and Drug Administration\">FDA<\/abbr> approval, followed in 2019 by its netarsudil \/ latanoprost <abbr title=\"fixed-dose combination\">FDC<\/abbr>, Rocklatan; both agents have since received <abbr title=\"European Medicines Agency\">EMA<\/abbr> approval in Europe. The current <abbr title=\"primary open-angle glaucoma\">POAG<\/abbr> pipeline is active and includes novel agents as well as alternative formulations of existing therapies with differing administration requirements. By examining the key treatment drivers and greatest areas of unmet need in <abbr title=\"primary open-angle glaucoma\">POAG<\/abbr> prescribing, this content presents the opportunities in this space.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are the treatment drivers and goals for <abbr title=\"primary open-angle glaucoma\">POAG<\/abbr>?<\/li>\n<li>What drug attributes are key influences, which have limited impact, and which are hidden opportunities?<\/li>\n<li>How do current therapies perform on key treatment drivers and goals for <abbr title=\"primary open-angle glaucoma\">POAG<\/abbr>?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in <abbr title=\"primary open-angle glaucoma\">POAG<\/abbr>?<\/li>\n<li>What trade-offs across different clinical attributes and price are acceptable to U.S. and European ophthalmologists for a hypothetical new <abbr title=\"primary open-angle glaucoma\">POAG<\/abbr> drug?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.<\/p>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 61 U.S. and 30 European ophthalmologists fielded in July 2023<\/p>\n<p><strong>Key companies:<\/strong> AbbVie \/ Allergan, Pfizer, Novartis, Merck &#038; Co, Viatris, <abbr title=\"T-helper cell\">Th<\/abbr>\u00e9a<\/p>\n<p><strong>Key drugs:<\/strong> Xalatan, Lumigan, timolol, Alphagan, Azopt, Combigan, Cosopt<\/p>\n","protected":false},"template":"","class_list":["post-249802","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-glaucoma","biopharma-therapy-areas-ophthalmology","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249802","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249802\/revisions"}],"predecessor-version":[{"id":576070,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249802\/revisions\/576070"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=249802"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}